# Canopy Growth Corp: financial statements, quarterly

CGC · Nasdaq · CIK 1737927 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Mar 31

Pages: [Overview](/companies/cgc.md) · [Financials](/companies/cgc/financials.md) · [Filings](/companies/cgc/filings.md) · [Insiders](/companies/cgc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cgc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [69.6](/filings/0001193125-26-270260.md) | [78.5](/filings/0001193125-26-270260.md) | [72.8 d](/filings/0001193125-26-270260.md) | [66.2](/filings/0001193125-26-270260.md) | [63.0](/filings/0001193125-26-270260.md) | [74.8](/filings/0001193125-26-270260.md) | [65.0 d](/filings/0001193125-26-270260.md) | [72.1](/filings/0001193125-26-339076.md) | [66.7](/filings/0001193125-26-270260.md) | [74.5](/filings/0001193125-26-270260.md) | [71.2 d](/filings/0001193125-26-270260.md) | [81.2](/filings/0001193125-26-339076.md) |
| Cost of revenue | $m | [46.2](/filings/0000950170-24-123672.md) | [50.3](/filings/0000950170-25-015839.md) | [57.3 d](/filings/0001193125-26-270260.md) | [43.2](/filings/0001193125-25-175982.md) | [41.2](/filings/0001193125-25-270960.md) | [50.7](/filings/0001193125-26-040275.md) | [54.5 d](/filings/0001193125-26-270260.md) | [54.1](/filings/0001193125-26-339076.md) | [44.8](/filings/0001193125-25-270960.md) | [53.1](/filings/0001193125-26-040275.md) | [63.0 d](/filings/0001193125-26-270260.md) | [58.9](/filings/0001193125-26-339076.md) |
| Gross profit | $m | [23.4](/filings/0001193125-26-270260.md) | [28.2](/filings/0001193125-26-270260.md) | [15.5 d](/filings/0001193125-26-270260.md) | [23.0](/filings/0001193125-26-270260.md) | [21.8](/filings/0001193125-26-270260.md) | [24.1](/filings/0001193125-26-270260.md) | [10.5 d](/filings/0001193125-26-270260.md) | [18.0](/filings/0001193125-26-339076.md) | [21.9](/filings/0001193125-26-270260.md) | [21.5](/filings/0001193125-26-270260.md) | [8.3 d](/filings/0001193125-26-270260.md) | [22.2](/filings/0001193125-26-339076.md) |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [57.6](/filings/0000950170-24-123672.md) | [54.4](/filings/0000950170-25-015839.md) | [54.6 d](/filings/0001193125-26-270260.md) | [48.0](/filings/0001193125-25-175982.md) | [41.7](/filings/0001193125-25-270960.md) | [41.5](/filings/0001193125-26-040275.md) | [38.5 d](/filings/0001193125-26-270260.md) | [38.1](/filings/0001193125-26-339076.md) | [36.3](/filings/0001193125-25-270960.md) | [44.4](/filings/0001193125-26-040275.md) | [41.1 d](/filings/0001193125-26-270260.md) | [40.2](/filings/0001193125-26-339076.md) |
| Operating income | $m | [(7.0)](/filings/0001193125-26-270260.md) | [(60.3)](/filings/0001193125-26-270260.md) | [(107) d](/filings/0001193125-26-270260.md) | [(29.1)](/filings/0001193125-26-270260.md) | [(45.9)](/filings/0001193125-26-270260.md) | [(23.8)](/filings/0001193125-26-270260.md) | [(18.3) d](/filings/0001193125-26-270260.md) | [(22.6)](/filings/0001193125-26-339076.md) | [(16.9)](/filings/0001193125-26-270260.md) | [(26.4)](/filings/0001193125-26-270260.md) | [(95.8) d](/filings/0001193125-26-270260.md) | [(22.1)](/filings/0001193125-26-339076.md) |
| Interest expense | $m | [27.4](/filings/0000950170-24-123672.md) | [24.6](/filings/0000950170-25-015839.md) | [21.1 d](/filings/0001193125-26-270260.md) | [21.1](/filings/0001193125-25-175982.md) | [21.3](/filings/0001193125-25-270960.md) | [16.8](/filings/0001193125-26-040275.md) | [15.4 d](/filings/0001193125-26-270260.md) | [9.7](/filings/0001193125-26-339076.md) | [8.8](/filings/0001193125-25-270960.md) | [7.3](/filings/0001193125-26-040275.md) | [12.3 d](/filings/0001193125-26-270260.md) | [12.7](/filings/0001193125-26-339076.md) |
| Income tax | $m | [12.8](/filings/0000950170-24-123672.md) | [(1.1)](/filings/0000950170-25-015839.md) | [(1.4) d](/filings/0001193125-26-270260.md) | [6.2](/filings/0001193125-25-175982.md) | [0.3](/filings/0001193125-25-270960.md) | [0.3](/filings/0001193125-26-040275.md) | [0.3 d](/filings/0001193125-26-270260.md) | [0.3](/filings/0001193125-26-339076.md) | [0.2](/filings/0001193125-25-270960.md) | [0.4](/filings/0001193125-26-040275.md) | [(0.9) d](/filings/0001193125-26-270260.md) | [(0.1)](/filings/0001193125-26-339076.md) |
| Net income | $m | [(316)](/filings/0001193125-26-270260.md) | [(206)](/filings/0001193125-26-270260.md) | [(148) d](/filings/0001193125-26-270260.md) | [(106)](/filings/0001193125-26-270260.md) | [(109)](/filings/0001193125-26-270260.md) | [(98.1)](/filings/0001193125-26-270260.md) | [(196) d](/filings/0001193125-26-270260.md) | [(44.9)](/filings/0001193125-26-339076.md) | [(5.0) d](/filings/0001193125-26-270260.md) | [(58.3) d](/filings/0001193125-26-270260.md) | [(155) d](/filings/0001193125-26-270260.md) | [(14.6)](/filings/0001193125-26-339076.md) |
| Diluted EPS | $ per share | [(4.21)](/filings/0001193125-26-270260.md) | [(2.49)](/filings/0001193125-26-270260.md) | not reported | [(1.33)](/filings/0001193125-26-270260.md) | [(1.26)](/filings/0001193125-26-270260.md) | [(0.89)](/filings/0001193125-26-270260.md) | not reported | [(0.24)](/filings/0001193125-26-339076.md) | [(0.02)](/filings/0001193125-26-270260.md) | [(0.17)](/filings/0001193125-26-270260.md) | not reported | [(0.03)](/filings/0001193125-26-339076.md) |
| Basic EPS | $ per share | [(4.21)](/filings/0001193125-26-270260.md) | [(2.49)](/filings/0001193125-26-270260.md) | not reported | [(1.33)](/filings/0001193125-26-270260.md) | [(1.26)](/filings/0001193125-26-270260.md) | [(0.89)](/filings/0001193125-26-270260.md) | not reported | [(0.24)](/filings/0001193125-26-339076.md) | [(0.02)](/filings/0001193125-26-270260.md) | [(0.17)](/filings/0001193125-26-270260.md) | not reported | [(0.03)](/filings/0001193125-26-339076.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [240](/filings/0000950170-23-062177.md) | [143](/filings/0000950170-24-013047.md) | [170](/filings/0001193125-26-270260.md) | [192](/filings/0000950170-24-094330.md) | [228](/filings/0000950170-24-123672.md) | [162](/filings/0000950170-25-015839.md) | [114](/filings/0001193125-26-270260.md) | [126](/filings/0001193125-25-175982.md) | [298](/filings/0001193125-25-270960.md) | [371](/filings/0001193125-26-040275.md) | [365](/filings/0001193125-26-339076.md) | [337](/filings/0001193125-26-339076.md) |
| Current assets | $m | [494](/filings/0000950170-23-062177.md) | [397](/filings/0000950170-24-013047.md) | [371](/filings/0001193125-26-270260.md) | [358](/filings/0000950170-24-094330.md) | [392](/filings/0000950170-24-123672.md) | [341](/filings/0000950170-25-015839.md) | [295](/filings/0001193125-26-270260.md) | [303](/filings/0001193125-25-175982.md) | [446](/filings/0001193125-25-270960.md) | [525](/filings/0001193125-26-040275.md) | [529](/filings/0001193125-26-339076.md) | [506](/filings/0001193125-26-339076.md) |
| Total assets | $m | [1,668](/filings/0000950170-23-062177.md) | [1,360](/filings/0000950170-24-013047.md) | [1,300](/filings/0001193125-26-270260.md) | [1,286](/filings/0000950170-24-094330.md) | [1,232](/filings/0000950170-24-123672.md) | [1,164](/filings/0000950170-25-015839.md) | [918](/filings/0001193125-26-270260.md) | [905](/filings/0001193125-25-175982.md) | [1,070](/filings/0001193125-25-270960.md) | [1,106](/filings/0001193125-26-040275.md) | [1,119](/filings/0001193125-26-339076.md) | [1,104](/filings/0001193125-26-339076.md) |
| Current liabilities | $m | [217](/filings/0001193125-26-270260.md) | [231](/filings/0001193125-26-270260.md) | [335](/filings/0001193125-26-270260.md) | [232](/filings/0001193125-26-270260.md) | [327](/filings/0001193125-26-270260.md) | [130](/filings/0001193125-26-270260.md) | [103](/filings/0001193125-26-270260.md) | [111](/filings/0001193125-26-270260.md) | [96.4](/filings/0001193125-26-270260.md) | [109](/filings/0001193125-26-270260.md) | [158](/filings/0001193125-26-339076.md) | [167](/filings/0001193125-26-339076.md) |
| Total liabilities | $m | [939](/filings/0001193125-26-270260.md) | [825](/filings/0001193125-26-270260.md) | [900](/filings/0001193125-26-270260.md) | [819](/filings/0001193125-26-270260.md) | [768](/filings/0001193125-26-270260.md) | [606](/filings/0001193125-26-270260.md) | [439](/filings/0001193125-26-270260.md) | [428](/filings/0001193125-26-270260.md) | [349](/filings/0001193125-26-270260.md) | [359](/filings/0001193125-26-270260.md) | [421](/filings/0001193125-26-339076.md) | [415](/filings/0001193125-26-339076.md) |
| Long-term debt | $m | [631](/filings/0000950170-23-062177.md) | [521](/filings/0000950170-24-013047.md) | [493](/filings/0001193125-26-270260.md) | [558](/filings/0000950170-24-094330.md) | [416](/filings/0000950170-24-123672.md) | [438](/filings/0000950170-25-015839.md) | [300](/filings/0001193125-26-270260.md) | [289](/filings/0001193125-25-175982.md) | [226](/filings/0001193125-25-270960.md) | [225](/filings/0001193125-26-040275.md) | [217](/filings/0001193125-26-339076.md) | [211](/filings/0001193125-26-339076.md) |
| Current portion of debt | $m | [50.0](/filings/0000950170-23-062177.md) | [91.3](/filings/0000950170-24-013047.md) | [104](/filings/0001193125-26-270260.md) | [2.5](/filings/0000950170-24-094330.md) | [138](/filings/0000950170-24-123672.md) | [3.2](/filings/0000950170-25-015839.md) | [4.3](/filings/0001193125-26-270260.md) | [6.3](/filings/0001193125-25-175982.md) | [1.8](/filings/0001193125-25-270960.md) | [0.0](/filings/0001193125-26-040275.md) | [16.2](/filings/0001193125-26-339076.md) | [28.8](/filings/0001193125-26-339076.md) |
| Shareholders' equity | $m | [729](/filings/0001193125-26-270260.md) | [535](/filings/0001193125-26-270260.md) | [400](/filings/0001193125-26-270260.md) | [467](/filings/0001193125-26-270260.md) | [464](/filings/0001193125-26-270260.md) | [558](/filings/0001193125-26-270260.md) | [479](/filings/0001193125-26-270260.md) | [477](/filings/0001193125-26-339076.md) | [721](/filings/0001193125-26-270260.md) | [747](/filings/0001193125-26-270260.md) | [698](/filings/0001193125-26-270260.md) | [689](/filings/0001193125-26-339076.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity, us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(78.7) d](/filings/0001193125-26-270260.md) | [(32.6) d](/filings/0001193125-26-270260.md) | [(22.1) d](/filings/0001193125-26-270260.md) | [(51.8)](/filings/0001193125-26-270260.md) | [(53.9) d](/filings/0001193125-26-270260.md) | [(27.0) d](/filings/0001193125-26-270260.md) | [(33.2) d](/filings/0001193125-26-270260.md) | [(10.3)](/filings/0001193125-26-339076.md) | [(18.0) d](/filings/0001193125-26-270260.md) | [(17.2) d](/filings/0001193125-26-270260.md) | [(18.3) d](/filings/0001193125-26-270260.md) | [(25.0)](/filings/0001193125-26-339076.md) |
| Capital expenditure | $m | [0.7 d](/filings/0000950170-24-123672.md) | [0.6 d](/filings/0000950170-25-015839.md) | [0.2 d](/filings/0001193125-26-270260.md) | [3.9](/filings/0001193125-25-175982.md) | [2.6 d](/filings/0001193125-25-270960.md) | [1.2 d](/filings/0001193125-26-040275.md) | [3.1 d](/filings/0001193125-26-270260.md) | [1.3](/filings/0001193125-26-339076.md) | [1.2 d](/filings/0001193125-25-270960.md) | [1.8 d](/filings/0001193125-26-040275.md) | [1.0 d](/filings/0001193125-26-270260.md) | [0.7](/filings/0001193125-26-339076.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q2 FY2023 (2022-09-30) | Q3 FY2023 (2022-12-31) | Q1 FY2024 (2023-06-30) | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [472](/filings/0000950170-23-062177.md) | [48.6](/filings/0000950170-24-013047.md) | [55.0](/filings/0000950170-24-094330.md) | [71.6](/filings/0000950170-24-123672.md) | [82.9](/filings/0000950170-25-015839.md) | [79.2](/filings/0001193125-25-175982.md) | [86.8](/filings/0001193125-25-270960.md) | [110](/filings/0001193125-26-040275.md) | [188](/filings/0001193125-26-339076.md) | [274](/filings/0001193125-25-270960.md) | [346](/filings/0001193125-26-040275.md) | [422](/filings/0001193125-26-339076.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 423,037,675 at 2026-08-05, from the cover of the [10-Q filed 2026-08-07](/filings/0001193125-26-339076.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.